Description
Lomustine is an alkylating chemotherapy agent belonging to the nitrosourea class of medications. While primarily used for brain tumors and Hodgkin's lymphoma, it has limited application in colorectal cancer treatment.
Mechanism of Action
Lomustine works by cross-linking DNA strands and interfering with RNA synthesis, ultimately leading to cancer cell death.
Side Effects
Severe bone marrow suppression (especially delayed thrombocytopenia and leukopenia)
Nausea and vomiting
Pulmonary fibrosis
Hepatotoxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT03678883
Phase 2
Active, not recruiting
9-ING-41 in Patients With Advanced Cancers
United States, Belgium, Canada, France, Netherlands, Portugal, Spain
Quick Info
| Brand Name | CeeNU, Gleostine |
| Category | Other Medications |
 EMA Status | EMA Approved |
 Spain Access | Hospital use |
| Clinical Trials | 1 |
Related Medications
Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.